• February 23, 2021

    SOFIA (Bulgaria), February 23 (SeeNews) – Bulgarian drug maker Tchaikapharma High Quality Medicines [BUL:7TH] said that its shareholders have approved its plan to borrow up to 14 million euro ($17.2 million) in order to finance the construction of a new production plant just outside Sofia.


    The proposal was supported by all shareholders present at the meeting, representing 99.88% of the total voting rights, Tchaikapharma said in a stock exchange filing on Monday.


    The loan, to be provided by local lender United Bulgarian Bank (UBB), will have an interest rate of between 2% and 3%. The eight-year loan agreement will have a three-year grace period.


    Read the original article here.

  • February 3, 2021

    At the beginning of February, one share of the company costs BGN 13.80, which means that the market capitalization of the pharmaceutical equals 1.13 billion leva.


    Read the full article here in Bulgarian.

  • December 22, 2020

    We say goodbye to a historic year, marked by unprecedented difficulties in medical, economical, political and of course, in pure human terms. With hard work and effective oganization, in this difficult time, we could assure that the Bulgarian population had access to reliable and affordable medical prevention and early COVID-19 treatment with hydroxychloroquine. At the same time, by developing, manufacturing and registering it in Bulgaria, we have restored access to thousands of patients suffering from lupus and rheumatoid arthritis to this essential medicine. Tchaikapharma is the only Bulgarian manufacturer of injectable antibiotics, which are vitally important for the hospitals in the country. Obviously, these achievements did not go unnoticed on the Bulgarian stock exchange.


    Read the original article here.

  • October 5, 2020

    Patients with rheumatic disease are less likely to suffer from coronavirus, especially those taking hydroxychloroquine. That is why their therapy should not be interrupted during the pandemic, says rheumatologist Prof. Rasho Rashkov and clarifies that he and his colleagues have many years of experience in the treatment with hydroxychloroquine, as well as treatment of some of the complications caused by the infection.

    The full article is available here in Bulgarian.

  • October 3, 2020

    Tchaikapharma High Quality Medicines Inc. remains the most expensive Bulgarian company on the Bulgarian Stock Exchange. After the market capitalization of the pharmaceutical company exceeded BGN 1 billion at the end of June, in July, August and September it added more value to its stock market valuation.


    The full article is available here in Bulgarian.